“An Extra Variable to Consider”—Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials

Fatola, OmolayoCorneli, AmyPerry, BrianHanlen-Rosado, EmilyNsonwu, AdoraConstantine, Evangelia P.Thompson, Amelia B.2023-10-312023-10-312022Fatola O, Corneli A, Perry B, et al. "An Extra Variable to Consider"-Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials. J Pediatric Infect Dis Soc. 2022;11(5):221-224. doi:10.1093/jpids/piac001https://hdl.handle.net/1805/36810Our study explores the understanding of vaccine-induced seropositivity (VISP) and its potential impact on US adolescents' and caregivers' willingness to participate in adolescent HIV vaccine clinical trials. Findings from in-depth interviews suggest that addressing concerns about VISP will be essential for future pediatric HIV vaccine trials in the United States.en-USPublisher PolicyAdolescentHIVPreventionVaccine-induced seropositivity (VISP)“An Extra Variable to Consider”—Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical TrialsArticle